- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Small Intestine Cancer - September 2002
National Cancer Institute®
Last Modified: September 1, 2002
- Isolated duodenal metastasis from breast carcinoma.
- [Upper gastrointestinal hemorrhage of unusual etiology: clinical case and technical note]
- Treatment of patients with gastric cancer and duodenal invasion.
- Primary ileal mucinous adenocarcinoma.
- Laparoscopically assisted panenteroscopy for snare excision.
- Jejunal interposition to prevent postgastrectomy syndromes.
- Lymphoma in an ileostomy.
- Small bowel adenocarcinoma presenting as a first manifestation of Crohn's disease: report of a case, and a literature review.
- [Malignant carcinoid of the last ileal ansa. Report on 2 consecutive clinical cases]
- [First experience with a non-covered CHOO enteral stent in the stomach,duodenum, and jejunum]
- [Recklinghausen's disease and gastrointestinal stromal tumors]
- Simultaneous duodenal and colon masses as late presentation of metastatic renal cell carcinoma.
- Unusual hematologic malignancies. Case 3. CNS involvement in CD56-positive intestinal gamma/delta T-cell lymphoma.
- Safety and outcome of endoscopic snare excision of the major duodenal papilla.
- Total colectomy and J-pouch ileorectal anastomosis for obstructed tumours of the rectosigmoid junction.
- [Clinicopathological and immunohistochemical characteristics of stromal sarcoma of the duodenum]
- Chemoembolization in the treatment of metastatic ileocolic carcinoid.
- A tumour with a neuroendocrine and papillary serous component: two or a pair?
Table of Contents
1
UI - 12126355
AU - Sarkar N; Kejariwal D; Roy S
TI -
Isolated duodenal metastasis from breast carcinoma.
SO - J Assoc Physicians India 2002 Jul;50():962-3
AD - Department of Medicine, IPGMER and SSKM Hospital, Calcutta.
Small bowel neoplasms comprise 0.1% of all malignancies. Of these
one-third are duodenal, mainly primary. Isolated duodenal secondaries
arising on account of haematogenous spread is rare. Our case of duodenal
obstruction due to an isolated duodenal metastasis as a result of
haematogenous spread from breast carcinoma is unique in the literature.
2
UI - 11873636
AU - Ansalone M; Aragiusto G; Romagnuolo G; Scardi F; Damiano I; Ambrosino F;
TI -
Giovine S
[Upper gastrointestinal hemorrhage of unusual etiology: clinical case
and technical note]
SO - G Chir 2001 Nov-Dec;22(11-12):385-8
AD - Unita Operativa di Chirurgia d'Urgenza e Pronto Soccorso, Azienda
Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli.
The Authors report a case of upper digestive tract haemorrhage at
atypical side, the diagnosis being often difficult as well as
therapeutical options, particularly referent to the surgical solutions
adopted.
3
UI - 11890346
AU - Ajisaka H; Fujita H; Kaji M; Maeda K; Yabushita K; Konishi K; Uchiyama
TI -
A; Miwa A
Treatment of patients with gastric cancer and duodenal invasion.
SO - Int Surg 2001 Jan-Mar;86(1):9-13
AD - Department of Surgery, Toyama Prefectural Central Hospital, Japan.
We retrospectively examined clinicopathologic features of gastric cancer
with duodenal invasion to clarify the effect of surgical treatment that
include pancreaticoduodenectomy (PD). Among 2504 patients with gastric
cancer, 69 (2.8%) who had gastric cancer and duodenal invasion resected
by surgical treatment were investigated. The mode of the duodenal
invasion was grouped into three categories: mucosal type, submucosal
type, and nodal type. Mucosal type is invasion of the duodenal mucosal
layer, submucosal type is invasion of the submucosal layer or deeper,
and nodal type is invasion from nodal metastatic lesions around the
pancreatic head. The 5-year survival rates of curative PD and curative
gastrectomy were 37.3% and 33.8%, respectively. Despite the incidence of
adjacent tissue infiltration and significantly higher duodenal invasion
average length in cases with PD than in cases with gastrectomy, there
was no significant difference in the survival curves. However, the
prognoses of the cases with nodal-type invasion were significantly
poorer, and all these patients died within 2 years, regardless of
whether curative PD had been performed. Curative PD improves the
prognosis of cases with long duodenal invasion or pancreas infiltration
except for nodal-type duodenal invasion.
4
UI - 12085045
AU - Iwasaki Y; Tagaya N; Tomita S; Fujimori T; Kubota K
TI -
Primary ileal mucinous adenocarcinoma.
SO - Gastrointest Endosc 2002 Jul;56(1):111
AD - Dokkyo University School of Medicine, Tochigi, Japan.
5
UI - 8858336
AU - Reddy ND; Rao VG
TI -
Laparoscopically assisted panenteroscopy for snare excision.
SO - Gastrointest Endosc 1996 Aug;44(2):208-9
6
UI - 11091248
AU - Morii Y; Arita T; Shimoda K; Yasuda K; Matsui Y; Inomata M; Kitano S
TI -
Jejunal interposition to prevent postgastrectomy syndromes.
SO - Br J Surg 2000 Nov;87(11):1576-9
AD - Surgery Division, Arita Gastrointestinal Hospital, Oita, Japan.
BACKGROUND: Postgastrectomy syndromes include reflux gastritis and
oesophagitis, dumping syndrome, intractable diarrhoea and afferent loop
interposition has been used following distal gastrectomy. The aim of
this study was to evaluate the benefit of this procedure. METHODS: A
consecutive series of 42 patients who underwent distal gastrectomy for
gastric cancer was studied. Twenty-two patients had a Billroth I
RESULTS: The mean operating time was 260 min for Billroth I and 352 min
for jejunal interposition. No serious postoperative complications arose.
Reflux gastritis occurred in 19 patients after Billroth I but in none
after jejunal interposition. Five patients in the Billroth I group had
complaints consistent with dumping syndrome, compared with none after
jejunal interposition. The barium gastric emptying time was
significantly shorter after Billroth I (mean(s.d.) 269(225)s) than after
jejunal interposition (736(479) s) (P < 0.01). CONCLUSION: Jejunal
interposition prevented reflux gastritis and inhibited rapid gastric
emptying. Postgastrectomy syndromes were effectively prevented by this
reconstruction procedure.
7
UI - 12151696
AU - Pranesh N
TI -
Lymphoma in an ileostomy.
SO - Postgrad Med J 2002 Jun;78(920):368-9
AD - Department of Surgery, Milton Keynes General Hospital, Standing Way,
Eaglestone, Milton Keynes MK6 5LD, UK. npranesh@hotmail.com
Lymphoma developing in an ileostomy is an extremely rare complication.
The presentation is similar to the commoner, yet still rare,
adenocarcinoma but the staging and management of the condition differs.
8
UI - 12169995
AU - Christodoulou D; Skopelitou AS; Katsanos KH; Katsios C; Agnantis N;
TI -
Price A; Kappas A; Tsianos EV
Small bowel adenocarcinoma presenting as a first manifestation of
Crohn's disease: report of a case, and a literature review.
SO - Eur J Gastroenterol Hepatol 2002 Jul;14(7):805-10
AD - Department of Internal Medicine, Hepato-Gastroenterology Unit, School of
Medicine, University of Ioannina, Ioannina 451 10, Greece.
Small bowel Crohn's disease has been related to an increased incidence
of small bowel adenocarcinoma, but the total number of reported cases is
small. We present an interesting case of a young male patient with
nephrolithiasis in childhood, an atypical intermittent history of
diarrhoea also since his childhood, who developed obstructive ileus and
underwent an urgent operation. The operation revealed a stenosis of the
ileum owing to a mass, which proved to be a small bowel adenocarcinoma.
One month later, the patient underwent a curative surgical resection of
the tumour with additional lymphadenectomy, followed by chemotherapy for
6 months. Since then, the patient had mild diarrhoea but enteroclysis
was normal. Approximately 2 years after the resection of the tumour, a
new ileocolonoscopy demonstrated deep ulcerations of the terminal ileum
and the adjacent area of the colon as well as anal ulcerations. The new
biopsy specimens were convincing for Crohn's disease. There were no
signs of residual or relapsing cancer. There is growing evidence that
Crohn's disease is one of the triggering factors for the development of
small bowel adenocarcinoma. Underlying Crohn's disease should be
suspected in a young patient with an atypical history of diarrhoea and
small bowel adenocarcinoma.
9
UI - 11941295
AU - Russo A; Buccianelli E; Aloise F; Veltroni A
TI -
[Malignant carcinoid of the last ileal ansa. Report on 2 consecutive
clinical cases]
SO - Minerva Chir 2002 Apr;57(2):203-11
AD - Area a Gestione Sperimentale della Valdinievole, Unita Operativa di
Chirurgia Generale, ASL n. 3, Pistoia, Presidio Ospedaliero SS. Cosma e
Damiano, Pescia (Pistoia), Italy.
Carcinoid tumors are very rare neoplasms, arising from enterochromaffin
cells, classified in Apud system, exhibiting an intermediate malignancy,
because of their long lasting clinical silence and low evolution to
advanced stage. At the same time, these features unfortunately cause a
high incidence of lymphatic and liver metastases, visible at first
diagnostic approach, which are also determined by aspecific symptoms and
signs, especially involving jejunal and ileal carcinoids, as the two
cases described, and by very frequent absence, in current clinical
practice, of pathognomonic carcinoid syndrome. Two carcinoids located
into the distal ileal ansa, strictly adjacent to the ileocecal valve,
are reported; the first tumor, accompanied by lymphonodal positivity,
the second by a solitary hepatic metastasis, requiring segmentectomy of
the liver, in addition to right hemicolectomy.
10
UI - 12142981
AU - Dorffner R; Neumann C; Gergely I; Stimakovits J; Renner R
TI -
[First experience with a non-covered CHOO enteral stent in the
stomach,duodenum, and jejunum]
SO - Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002
Aug;174(8):1018-21
AD - Rontgenabteilung, Osterreich, Germany.
AIM: To evaluate the technical performance of the non-covered CHOO
enteral stent in the stomach, duodenum and jejunum. METHODS: In 8
patients (two men, 6 women) with malignant tumors of the stomach (n =
4), duodenum (n = 3) and jejunum (n = 1) stent implantation was
performed under fluoroscopic control. In two patients endoscopy was
needed additionally. The patients were followed for 1 to 168 days.
RESULTS: Stent implantation was technically successful in 7 of 8
patients. In 6 patients symptoms improved. In two patients a second
stent implantation was necessary 35 and 161 days after primary
implantation, respectively. There was no stent migration or tumor
ingrowth. CONCLUSION: The implantation of the non-covered CHOO enteral
stent into the upper gastrointestinal tract is safe and effective.
11
UI - 12122722
AU - Giuly J; Monges B; Picaud R; Giuly D; Leroux C; Cat RN
TI -
[Recklinghausen's disease and gastrointestinal stromal tumors]
SO - Ann Chir 2002 Jun;127(6):477-9
AD - Clinique Fallen, boulevard Val-Pre, 13400 Aubagne, France.
Gastro-intestinal stromal tumors associated with Recklinghausen's
disease should be considered in the current concept of the stromal
tumors with reference to recent advances in immuno-chemistry. In this
setting, there is an high potential of maluignancy. For the treatment of
these lesions, surgery is the main tool. Frequency of malignant
digestive diseases associated with Recklinghausen disease should be kept
in mind.
12
UI - 12164092
AU - Lee JG; Kim JS; Kim HJ; Kim ST; Yeon JE; Byun KS; Kim JS; Bak YT; Lee CH
TI -
Simultaneous duodenal and colon masses as late presentation of
metastatic renal cell carcinoma.
SO - Korean J Intern Med 2002 Jun;17(2):143-6
AD - Department of Internal Medicine, College of Medicine, Korea University,
Seoul, Korea.
We report a case of pathologically proven simultaneous duodenal and
colonic metastases about four years after nephrectomy for mixed clear
and granular cell type renal cell carcinoma (RCC). A 76-year-old female
patient who had undergone a left radical nephrectomy 4 years previously
for RCC presented with a 1-month history of dyspepsia and pain in the
right upper abdomen. An abdominopelvic CT scan showed circumferential
wall thickening with high enhancement at the second portion of the
duodenum and additional enhancement of an irregular protruding mass into
the lumen of the ascending colon. A gastroscopy showed a large and
ulcerative protruding mass nearly obstructing the second portion of the
duodenum. A colonoscopy revealed a polypoid, nodular and purplish mass
in the ascending colon. Microscopy of the biopsy specimen showed the
features identical to those of the RCC which was resected 4 years
earlier in this patient. We believe this to be the first case
illustrating a metastatic renal cell carcinoma as simultaneous duodenal
and colon masses.
13
UI - 12202676
AU - Chim CS; Lam CC; Nicholls JM; Ooi GC; Kwong YL
TI -
Unusual hematologic malignancies. Case 3. CNS involvement in
CD56-positive intestinal gamma/delta T-cell lymphoma.
SO - J Clin Oncol 2002 Sep 1;20(17):3742-4
AD - Queen Mary Hospital, Hong Kong.
14
UI - 12145603
AU - Norton ID; Gostout CJ; Baron TH; Geller A; Petersen BT; Wiersema MJ
TI -
Safety and outcome of endoscopic snare excision of the major duodenal
papilla.
SO - Gastrointest Endosc 2002 Aug;56(2):239-43
AD - Developmental Endoscopy Unit, Division of Gastroenterology and
Hepatology, Mayo Clinic, Rochester, Minnesota 55902, USA.
BACKGROUND: The optimal management of adenoma of the major duodenal
papilla is not established. Options include surgical excision,
endoscopic ablative techniques, snare excision, and observation with
periodic biopsies. The aims of this retrospective study were to
determine the safety and outcome of snare excision of the papilla.
METHODS: Twenty-eight snare excisions of the papilla were performed in
26 patients. Sixteen had familial adenomatous polyposis. In 22
procedures, a minisnare was used, and in 6 cases a prototype snare was
designed for excision of the papilla. Pancreatic stents were placed as a
prophylactic measure at the discretion of the endoscopist (n = 10).
RESULTS: Histopathologically, resected tissue included 25 adenomas, 1
inflammatory polyp, 1 invasive malignancy, and 1 normal papilla.
Immediate complications were minor bleeding (n = 2), mild pancreatitis
(n = 4) and a duodenal perforation (n = 1). The presence (n = 10) or
absence (n = 18) of a pancreatic stent did not correlate with subsequent
pancreatitis (2 in each group, p = NS). Follow-up was available for 21
patients (median, 9 months; range, 2-32 months). Pancreatic duct
stenosis at the papillectomy site resulted in pancreatitis in 2 patients
(17%) at, respectively, 4 months and 24 months. Follow-up endoscopy
revealed recurrent/residual adenomatous tissue in 2 (10%). CONCLUSIONS:
Snare excision of the major duodenal papilla was well tolerated. Most
complications were mild except for a small duodenal perforation.
Stenosis of the pancreatic duct orifice with pancreatitis may be a late
complication.
15
UI - 12074083
AU - Chrysos E; Athanasakis E; Vassilakis JS; Zoras O; Xynos E
TI -
Total colectomy and J-pouch ileorectal anastomosis for obstructed
tumours of the rectosigmoid junction.
SO - ANZ J Surg 2002 Feb;72(2):92-4
AD - Department of General Surgery, University Hospital of Heraklion, Medical
School, University of Crete, Greece. chrysos@danae.med.uoc.gr
BACKGROUND: Subtotal colectomy with ileosigmoid or ileorectal
anastomosis is one of the standard procedures for obstructed tumours of
the left colon. The lower the level of the anastomosis, the greater the
number of bowel motions per day. The aim of the present study was to
assess whether an ileal pouch-rectal anastomosis is associated with
fewer bowel motions per day. METHODS: In four patients with obstructed
carcinoma of the rectosigmoid junction and upper rectum, a total
colectomy with removal of the upper rectum for adequate tumour clearance
was used, followed by construction of a 10 cm ileal J-pouch that was
subsequently anastomosed to the distal rectal stump. RESULTS:
Postoperative recovery was uneventful in all patients. At 3 months
postoperatively, anorectal manometry showed anal resting and squeeze
pressures at lower normal limits and a neorectal capacity ranging from
160 to 310 mL. One year postoperatively, all patients experienced one to
three normal bowel motions daily and no episodes of incontinence.
CONCLUSIONS: Total colectomy with ileal J-pouch-rectal anastomosis is a
reasonable operative alternative in cases with obstructed tumours of the
rectosigmoid junction, which necessitate removal of the upper rectum.
16
UI - 12185648
AU - Padilla D; Cubo T; Garcia M; Ortega G; Ramia JM; Martin J; Pardo R;
TI -
Lopez A; Hernandez Calvo J
[Clinicopathological and immunohistochemical characteristics of stromal
sarcoma of the duodenum]
SO - Rev Esp Enferm Dig 2002 Feb;94(2):104-5
17
UI - 12145671
AU - Diculescu M; Atanasiu C; Arbanas T; Croitoru A; Mihalcea A; Becheanu G;
TI -
Costinean S; Gheorghe L; Capsa R
Chemoembolization in the treatment of metastatic ileocolic carcinoid.
SO - Rom J Gastroenterol 2002 Jun;11(2):141-7
AD - Centre of Gastroenterology and Hepatology, Fundeni Clinical Institute,
Sos. Fundeni no. 258, 72437 Bucharest, Romania.
Carcinoid tumours are enigmatic, slow growing malignancies, which occur
most frequently (74%) in the gastrointestinal tract. Symptoms of the
carcinoid syndrome (flushing and diarrhoea) are infrequent, occurring in
approximately 10% of the patients with small bowel carcinoid. A
45-year-old patient with multiple liver metastases, diagnosed in 1994
with nonHodgkin's lymphoma after undergoing surgery for a distal ileal
tumour, was referred to us by the Department of Haematology. At that
moment the issue of a differential diagnosis with a carcinoid tumour
arose, due to the long evolution and lack of evidence to support the
initial diagnosis. The carcinoid syndrome was in fact present (the
patient experiencing flush after small amounts of alcohol and emotions)
and also we identified elevated values of 5HIAA. Reevaluation of the
histologic sections of the ileal tumour as well as an ultrasound guided
fine needle aspiration of an intrahepatic lesion confirmed the diagnosis
of "carcinoid tumour". This conclusion lead to new therapeutic options
for this patient. One of the main therapeutic options used in treating
multiple liver metastases from a carcinoid tumour is chemoembolization
and this case offered an excellent opportunity to present this therapy.
18
UI - 12195006
AU - Van Eeden S; Nederlof PM; Taal BG; Offerhaus GJ; Van Velthuysen ML
TI -
A tumour with a neuroendocrine and papillary serous component: two or a
pair?
SO - J Clin Pathol 2002 Sep;55(9):710-4
AD - Academic Medical Center, Department of Pathology, Meibergdreef 9, 1105
AZ Amsterdam, The Netherlands. S.vaneeden@amc.uva.nl
AIMS: To examine the clonal origin of a tumour, made up of a
neuroendocrine component and a papillary serous component by comparing
the pattern of loss of heterozygosity (LOH) and the immunohistochemical
protein expression of both components. METHODS/RESULTS: A 70 year old
woman, known to have a metastasised neuroendocrine carcinoma, underwent
resection of the distal part of the ileum because of obstruction by a
mesenterial mass. The macroscopically homogeneous mesenterial mass
consisted histologically of an admixture of a neuroendocrine component
and a papillary serous carcinoma. Loss of heterozygosity (LOH) analysis
of both components with a panel of 15 polymorphic microsatellite markers
showed a distinctive pattern of LOH, and both components showed LOH on
chromosome 4q and 17, but involving different alleles at the same locus.
Moreover, both components showed different immunohistochemical staining
patterns for neuroendocrine markers, cytokeratin 7, carcinoembryonic
antigen, and CA125. CONCLUSION: Both LOH analysis of the neuroendocrine
and papillary serous components of this tumour and the
immunohistochemical profile of both components are consistent with a
different clonal origin. The tumour is probably a collision tumour, in
which the papillary serous carcinoma must have been of peritoneal origin
because necropsy revealed a normal uterus and normal ovaries.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
